In this episode of GN in Ten, hosted by Dr. Kenar Jhaveri and Dr. Koyal Jain, takes a deep dive into the specialized world of pediatric glomerular disease. Joining the show are world-renowned pediatric nephrologists Dr. Louise Oni (Great Ormond Street Hospital, London) and Dr. Jun Oh (University of Hamburg, Germany) to discuss the "pediatric lag" in drug development and the massive global efforts currently underway to bring targeted therapies to children.

Key Highlights

• The C3G Breakthrough: Discussion on the "wave of excitement" following adult trials for iptacopan and pegcetacoplan, and how these results are paving the way for pediatric use.
• SGLT2 Inhibitors in Children: Insights into the collaborative global effort that overcame initial industry waivers to launch a landmark clinical trial for SGLT2 inhibitors in children aged 2–17.
• Challenges in Rare Disease: Why international collaboration and registries are vital for treating ultra-rare conditions like Anti-GBM disease and C3G in small pediatric populations.
• The Future of Genetics: A look toward the next 15 years, where genetic screening may shift the focus from treating active disease to early prevention.
• Managing Long-term Immunosuppression: The delicate balance of using B-cell depletion (Rituximab) in developing immune systems to preserve "childhood" and avoid dialysis.

Featured Guests

• Dr. Louise Oni: Professor of Pediatric Nephrology at Great Ormond Street and Chair of the ESPN Glomerular Disease Working Group.
• Dr. Jun Oh: Professor of Pediatrics at the University of Hamburg and a leader in the ISGD Pediatric Committee.

Resources & Mentioned Studies

• International Society of Glomerular Disease (ISGD): Learn more about the society’s mission and join for free!
• ESPN Glomerular Disease Working Group: Clinical research and educational resources for pediatric nephrologists.
• NephCure: A key partner in driving global pediatric clinical trials and supporting families affected by rare kidney disease.
• APPEAR-C3G Trial (Iptacopan): Phase 3 study evaluating the first approved treatment for C3G.
• VALIANT Trial (Pegcetacoplan):  Recent Phase 3 results showing success in both adult and adolescent patients (12+), published in the New England Journal of Medicine.